Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Atea Pharmaceuticals, Inc. - common stock (NQ: AVIR )

3.350 +0.020 (+0.60%)
Streaming Delayed Price Updated: 11:11 AM EST, Dec 30, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Atea Pharmaceuticals, Inc. - common stock

< Previous 1 2 3 4 5 6 7 Next >
3 Stocks That Might Soar With Pills for COVID
Are we seeing a major shift into oral medications for COVID? Our Foolish roundtable picks three of the strongest stocks in this rising subsector. 
Via The Motley Fool
Mid-Afternoon Market Update: Nasdaq Rises Over 100 Points; Biomerica Shares Spike Higher
Toward the end of trading Friday, the Dow traded up 1.49% to 34,346.53 while the NASDAQ rose 0.75% to 14,556.92. The S&P also rose, gaining 1.18% to 4,358.52. The U.S. has the... 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Biomerica (NASDAQ:BMRA) stock moved upwards by 39.33% to $6.27 during Friday's regular session. As of 12:30 EST, Biomerica's stock is trading at a volume... 
Via Benzinga
Mid-Day Market Update: Dow Surges 300 Points; Omeros Shares Plummet
Midway through trading Friday, the Dow traded up 0.88% to 34,141.74 while the NASDAQ rose 0.12% to 14,465.49. The S&P also rose, gaining 0.58% to 4,332.44. The U.S. has the... 
Via Benzinga
Topics Stocks
Exposures US Equities
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,... 
Via Benzinga
Exposures Product Safety
Why Atea Pharmaceutical Stock Is Ripping Higher Today
This biotech's experimental COVID-19 medication could be a big winner. 
Via The Motley Fool
Exposures COVID-19
Mid-Morning Market Update: Markets Mostly Higher; ISM Manufacturing Index Rises In September
Following the market opening Friday, the Dow traded up 0.49% to 34,010.27 while the NASDAQ fell 0.23% to 14,415.00. The S&P also rose, gaining 0.16% to 4,314.50. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures US Equities
Merck Stock Surges Into Buy Zone As Covid Pill Reduces Risk Of Death, Hospitalization
Merck said its Covid pill, molnupiravir, cut the risk of death and hospitalization by half. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Progenity (NASDAQ:PROG) stock increased by 21.06% to $1.31 during Thursday's regular session. The current volume of 70.4 million shares is 943.37% of Progenity... 
Via Benzinga
48 Biggest Movers From Yesterday
Gainers Edesa Biotech, Inc. (NASDAQ: EDSA) shares climbed 102.7% to settle at $11.92 on Monday after the company disclosed Phase 2 data of its monoclonal antibody in hospitalized... 
Via Benzinga
Why Atea Pharmaceuticals Is Up 17% Today
Orally administered treatments of COVID-19 infections are coming into focus as vaccine stocks lose their luster. 
Via The Motley Fool
Exposures COVID-19
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Atea Pharmaceuticals (NASDAQ:AVIR) shares increased by 13.83% to $29.86 during Monday's regular session. Trading volume for this security as of 12:30 EST is 3.... 
Via Benzinga
35 Stocks Moving In Monday's Mid-Day Session
Gainers ZIVO Bioscience, Inc. (NASDAQ: ZIVO) jumped 145% to $6.86 after declining around 17% on Friday. Edesa Biotech, Inc. (NASDAQ: EDSA) jumped 30.6% to $7.68 after the company... 
Via Benzinga
Atea Unveils Trial Amendments, New Data For COVID-19 Program
Atea Pharmaceuticals Inc (NASDAQ: AVIR) has unveiled some changes to its AT-527 COVID-19 Phase 2 program to keep up with the "evolving COVID-19 environment.... 
Via Benzinga
Exposures COVID-19
Atea Pharmaceuticals Inc (AVIR) Q2 2021 Earnings Call Transcript
AVIR earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Biolase (NASDAQ:BIOL) shares mov... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2021
Upgrades According to Benchmark, the prior rating for TopBuild Corp (NYSE: 
Via Benzinga
This High-Risk, High-Reward Biotech Could Make COVID Less Deadly -- and Make Investors Money
An effective oral antiviral therapy for the coronavirus may be around the corner. 
Via The Motley Fool
Exposures COVID-19
The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 11) Adagio Therapeutics, Inc. (... 
Via Benzinga
Exposures Product Safety
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Alector (NASDAQ:ALEC) shares moved upwards by 52.47% to $34.17 during Friday's regular session. Alector's stock is trading at a volume of 26.9 million... 
Via Benzinga
Atea Pharma's AT-527 Rapidly Reduces Viral Load Levels In Hospitalized COVID-19 Patients
Atea Pharmaceuticals Inc (NASDAQ: AVIR) has announced positive interim results from a Phase 2 study evaluating AT-527 in hospitalized patients with mild-to-... 
Via Benzinga
Exposures COVID-19
Atea Pharma Secures AT-527-Related Milestone Payment Of $50M From Roche
Atea Pharmaceuticals Inc (NASDAQ: AVIR) has achieved a development milestone associated with AT-527 and expects to receive a related payment under its license... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Atea Pharmaceuticals (NASDAQ:AVIR) stock moved upwards by 24.11% to $23.86 during Friday's regular session. The current volume of 967.7K shares is 156.13% of... 
Via Benzinga
74 Biggest Movers From Friday
Gainers MoSys, Inc. (NASDAQ: MOSY) shares climbed 50.5% to settle at $4.35 on Friday. MoSys, last week, reported a loss for its first quarter. HyreCar Inc. (NASDAQ: HYRE) shares... 
Via Benzinga
The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 13) Alexion Pharmaceuticals, Inc... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Merck Reports Positive Keytruda Data In Breast Cancer, Curis, Evoke Slump On Earnings, Qiagen's Rapid COVID-19 Antibody Test OK'ed For Emergency Use
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 12) Alexion Pharmaceuticals, Inc... 
Via Benzinga
Exposures COVID-19
The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 11) HOOKIPA Pharma Inc. (NASDAQ... 
Via Benzinga
Exposures COVID-19
The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 10) AbbVie Inc. (NYSE: ABBV) -... 
Via Benzinga
Exposures COVID-19 Product Safety
The Week Ahead In Biotech (May 9-15): Heron, Apellis FDA Decisions, Presentations and Earnings
Biotech stocks came under pressure in the week ended May 7 as traders digested a slew of earnings news flow and a handful of clinical trial readouts. COVID-19 vaccine stocks came... 
Via Benzinga
Exposures COVID-19 Product Safety
The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 6) GT Biopharma, Inc. (NASDAQ:... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.